SELL TO SCIENTISTS.

Industry Profile

Nuclear Medicine and Radiopharmaceuticals

Target researchers — Radiochemists, nuclear medicine physicians, and medicinal chemists specializing in radiolabeling of targeting vectors, PET tracer design, radiopharmaceutical synthesis automation, SPECT/PET imaging biomarker validation, and targeted radionuclide therapy

Nuclear medicine uses radioactive isotopes attached to targeting molecules for diagnosis via PET and SPECT and therapy through targeted radionuclide therapy of cancer and neurological disease. University radiochemistry and medical physics departments develop new chelation chemistries, targeting peptides, and radiolabeling automation platforms that companies license for clinical radiopharmaceutical pipelines.

$6.8B Market size
10 Key companies
6 Use cases

Key Companies

GE Healthcare Radiopharmaceuticals Lantheus Holdings Bracco Imaging POINT Biopharma RayzeBio BMS RadioMedix Curium Pharma ITM Isotope Technologies IONETIX Blue Earth Diagnostics

Use Cases

01

PET tracer precursor supply

02

Novel radionuclide-chelator licensing

03

Radiopharmaceutical synthesis automation

04

Alpha and beta-emitter radionuclide sourcing

05

Tumor-targeting vector co-development

06

GMP radiolabeling CRO services

Free to browse · subscribe to unlock the full dataset

See the full dataset.

Create a free account to search every researcher, set alerts, and export verified contacts to CSV / API.

Sign Up Free →
Get Started